Wednesday August 23rd 2017

Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

In conclusion, effective natalizumab treatment of RRMS patients was associated with the persistence of its biological effects through a stable increase of peripheral lymphocytes, mainly B cells, and an unchanged proportion of T cell subsets in long follow up. (Source: Clinical and Experimental Immunology)

See original – 

Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

Previous Topic:

Leave a Comment

More from category

Novartis launches MS study using data collected from smartphones
Novartis launches MS study using data collected from smartphones

Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing [Read More]

McDonald criteria: MS diagnosis guidelines
McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Multiple sclerosis: Are we close to a cure?
Multiple sclerosis: Are we close to a cure?

Read this article: Multiple sclerosis: Are we close to a cure? [Read More]

Medical News Today: McDonald criteria: MS diagnosis guidelines
Medical News Today: McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Medical News Today: Multiple sclerosis: Are we close to a cure?
Medical News Today: Multiple sclerosis: Are we close to a cure?

Discoveries and breakthroughs in multiple sclerosis research are building momentum, but just how close are we to [Read More]